This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cerevel Therapeutics Holdings Résultats passés
Passé contrôle des critères 0/6
Cerevel Therapeutics Holdings's earnings have been declining at an average annual rate of -30.8%, while the Biotechs industry saw earnings growing at 16.1% annually.
Informations clés
-30.8%
Taux de croissance des bénéfices
-3.6%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | n/a |
| Rendement des fonds propres | -81.6% |
| Marge nette | n/a |
| Dernière mise à jour des bénéfices | 31 Mar 2024 |
Mises à jour récentes des performances passées
Recent updates
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?
Apr 30
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Ventilation des recettes et des dépenses
Comment Cerevel Therapeutics Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -460 | 127 | 363 |
| 31 Dec 23 | 0 | -433 | 113 | 335 |
| 30 Sep 23 | 0 | -393 | 96 | 319 |
| 30 Jun 23 | 0 | -397 | 94 | 305 |
| 31 Mar 23 | 0 | -388 | 91 | 303 |
| 31 Dec 22 | 0 | -352 | 88 | 280 |
| 30 Sep 22 | 0 | -318 | 78 | 247 |
| 30 Jun 22 | 0 | -280 | 69 | 216 |
| 31 Mar 22 | 0 | -243 | 61 | 180 |
| 31 Dec 21 | 0 | -225 | 58 | 162 |
| 30 Sep 21 | 0 | -196 | 45 | 144 |
| 30 Jun 21 | 0 | -173 | 44 | 128 |
| 31 Mar 21 | 0 | -146 | 41 | 113 |
| 31 Dec 20 | 0 | -148 | 40 | 103 |
| 30 Sep 20 | 0 | -175 | 48 | 95 |
| 30 Jun 20 | 0 | -172 | 45 | 88 |
| 31 Mar 20 | 0 | -151 | 40 | 73 |
| 31 Dec 19 | 0 | -128 | 33 | 50 |
Des revenus de qualité: CERE is currently unprofitable.
Augmentation de la marge bénéficiaire: CERE is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CERE is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.
Accélération de la croissance: Unable to compare CERE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CERE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-34.5%).
Rendement des fonds propres
ROE élevé: CERE has a negative Return on Equity (-81.58%), as it is currently unprofitable.